Hypogonadotropic Hypogonadism
📧 Sign up to get email alerts when something new happens for Hypogonadotropic Hypogonadism.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2013-12-19FDA Approved: GONAL-F — Supplemental Application (EMD Serono, Inc.)
The FDA approved a supplemental application for GONAL-F (follitropin alfa) submitted by EMD Serono, Inc. The action updates the product's la…
-
FDA approval · 2013-09-20FDA Approved: GONAL-F — Supplemental Application (EMD Serono, Inc.)
The FDA approved a supplemental application for GONAL-F (follitropin alfa) from EMD Serono, Inc., authorizing changes to its labeling and/or…
-
CLINICAL_TRIALS trial_result · 2013-07-12Clinical Trial Update: Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L]) [Phase 4]
Phase 4 trial of Luveris (lutropin alfa) in women with hypogonadotropic hypogonadism was terminated. Results were posted in July 2013.
-
FDA approval · 2013-02-08FDA Approved: GONAL-F — Supplemental Application (EMD Serono, Inc.)
The FDA approved a supplemental application for GONAL-F (folitropin alfa) submitted by EMD Serono, Inc.
-
FDA approval · 2013-01-31FDA Approved: GONAL-F — Supplemental Application (EMD Serono, Inc.)
The FDA approved a supplemental application for GONAL-F (follitropin alfa) submitted by EMD Serono, Inc.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2013-01-31FDA Approved: GONAL-F RFF REDI-JECT — Supplemental Application (EMD Serono, Inc.)
FDA approved a supplemental application for GONAL-F RFF REDI-JECT (follitropin) submitted by EMD Serono, Inc. The action approves changes to…
-
FDA approval · 2013-01-23FDA Approved: GONAL-F — Supplemental Application (EMD Serono, Inc.)
FDA approved a supplemental application for GONAL-F (follitropin alfa) submitted by EMD Serono, Inc., typically to modify labeling or expand…
-
FDA label_change · 2013-01-18FDA Approved: GONAL-F — Supplemental Application (EMD Serono, Inc.)
FDA approved a supplemental application for GONAL-F (follitropin alfa) to update the labeling for the product.
-
FDA approval · 2013-01-11FDA Approved: GONAL-F RFF REDI-JECT — Supplemental Application (EMD Serono, Inc.)
The FDA approved a supplemental application for GONAL-F RFF REDI-JECT, a redesigned auto-injector formulation of follitropin alfa, expanding…
-
CLINICAL_TRIALS trial_result · 2012-06-20Clinical Trial Update: Clinical Outcomes in WHO Type I Anovulatory Women Using r-hFSH+r-hLH in a 2:1 Ratio or hMG-HP [NA]
Clinical trial outcomes for WHO Type I anovulatory women treated with recombinant FSH and LH in a 2:1 ratio or with HP-hMG were reported; th…
-
CLINICAL_TRIALS trial_result · 2012-05-22Clinical Trial Update: A Study Using Recombinant Human Luteinizing Hormone (r-hLH, Luveris®) in the Treatment of Chinese Women With Hypogonadotropic Hypogonadism [Phase 3]
Phase 3 study evaluating recombinant human luteinizing hormone (Luveris) for treating hypogonadotropic hypogonadism in Chinese women; the tr…
-
CLINICAL_TRIALS trial_result · 2010-10-22Clinical Trial Update: Short-term Effects of Aromatase Inhibition in Obese Men [Phase 3]
Phase 3 clinical trial completed evaluating the short-term effects of aromatase inhibition in obese men.
-
FDA approval · 2010-06-28FDA Approved: FOLLISTIM AQ — Supplemental Application (Organon LLC)
The FDA approved a supplemental application for FOLLISTIM AQ (folllitropin) from Organon LLC.
-
CLINICAL_TRIALS trial_result · 2008-06-16Clinical Trial Update: Clomiphene in Males With Prolactinomas and Persistent Hypogonadism [Phase 2]
A Phase 2 trial evaluating clomiphene in men with prolactinomas and persistent hypogonadism has completed.